Key points
- Record revenue of A$13.2M, up 45% from FY2025
- Strong growth in US market with 70 hospitals and 76 surgeons using Remplir
- Expanded international presence with first sales in Canada, Hong Kong, and Thailand
- Secured first right of refusal over PearlBone distribution
- Approved first stage of manufacturing expansion in Perth
Full summary
Orthocell Ltd has released its Annual Report for the financial year ended 30 June 2026, highlighting significant growth and strategic advancements. The company reported record revenue of A$13.2 million, a 45% increase from the previous year, driven by the continued adoption of its collagen medical devices across established markets and the early contributions from new international markets. The US market showed notable progress with Remplir being used by 76 surgeons across 70 hospitals, supported by strong surgeon feedback. Internationally, Orthocell expanded its presence with first sales in Canada, Hong Kong, and Thailand, and secured a first right of refusal over PearlBone distribution. The company also approved the first stage of expansion at its Perth manufacturing facility to support future international demand.